IQVIA (NYSE:IQV) Insider Keriann Cherofsky Sells 558 Shares

IQVIA Holdings Inc. (NYSE:IQV) insider Keriann Cherofsky sold 558 shares of IQVIA stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the sale, the insider owned 2,989 shares in the company, valued at $732,932.69. This trade represents a 15.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

IQVIA Stock Performance

NYSE:IQV traded down $2.69 during trading on Friday, reaching $235.09. The company’s stock had a trading volume of 1,321,730 shares, compared to its average volume of 1,815,732. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $251.36. The firm has a market cap of $39.24 billion, a price-to-earnings ratio of 29.17, a price-to-earnings-growth ratio of 2.20 and a beta of 1.20. The firm has a 50 day moving average of $193.41 and a 200-day moving average of $186.86. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.75 and a current ratio of 0.71.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. The company had revenue of $4.37 billion for the quarter, compared to analysts’ expectations of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The business’s revenue for the quarter was up 8.7% compared to the same quarter last year. During the same period in the previous year, the business posted $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Research analysts expect that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA declared that its board has authorized a share buyback plan on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s leadership believes its shares are undervalued.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Barclays restated an “overweight” rating on shares of IQVIA in a research note on Tuesday. Robert W. Baird increased their price objective on IQVIA from $252.00 to $287.00 and gave the company an “outperform” rating in a report on Wednesday. Evercore reissued an “outperform” rating and issued a $185.00 target price on shares of IQVIA in a research report on Wednesday, April 8th. Mizuho upped their price target on IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Finally, TD Cowen increased their price target on IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and a consensus target price of $241.88.

Institutional Investors Weigh In On IQVIA

Several institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in shares of IQVIA by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 19,650,532 shares of the medical research company’s stock worth $4,429,426,000 after acquiring an additional 159,899 shares during the period. Geode Capital Management LLC raised its stake in shares of IQVIA by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 4,374,971 shares of the medical research company’s stock valued at $982,272,000 after purchasing an additional 24,453 shares during the period. Boston Partners lifted its holdings in IQVIA by 14.9% during the 4th quarter. Boston Partners now owns 4,087,380 shares of the medical research company’s stock worth $923,276,000 after purchasing an additional 530,672 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in IQVIA by 16.2% during the 4th quarter. JPMorgan Chase & Co. now owns 3,799,600 shares of the medical research company’s stock worth $856,468,000 after purchasing an additional 528,753 shares in the last quarter. Finally, Invesco Ltd. boosted its stake in IQVIA by 15.3% in the 3rd quarter. Invesco Ltd. now owns 2,773,984 shares of the medical research company’s stock worth $526,891,000 after purchasing an additional 367,204 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.